Research

Drug Trials to Date

– Acuity: A randomized comparison of Angiomax vs. Lovenox in patients
   undergoing PCI for ACS without ST-segment elevation

– Jumbo: Joint Utilization of Medications to Block Platelets Optimally,
   Dose-Ranging Trial of CS-747 vs. plavix in subjects undergoing PCI

– Omnicarbon: Registry for follow-up of patients utilizing the Omnicarbon
   Cardiac Valve, Left Ventricular Mass Regression within the first
   post-operative year

– Advancent: National Registry to Advance Heart Health, CHF registry

– Finesse: Facilitated Intervention with Enhanced Reperfusion Speed to
   Stop Events, Acute MI

– Clarity: Clopidogrel as adjunctive reperfusion therapy thrombolysis in MI,
   acute MI

– Replace I and II: Angiomax in patients undergoing PCI

– Impact: cholesterol study

– Synergy: Comparing Lovenox to heparin in ACS

– Nasdac: cholesterol study

– Comply: Complement Inhibition in MI treated with thrombolytics

– Step-AMI: acute MI study

– Prove-It: cholesterol and Chlamydia treatment study

– Prince: cholesterol study

– Target: comparison of aggrastat and reopro in patients undergoing PCI

– OAT: NIH study looking at medical therapy vs. PCI in patients who have
   had a MI within the past 3-28 days with an occluded artery

– Cachet: randomized trial comparing hirulog and provisional reopro to
  planned reopro and low-dose heparin in patients undergoing PCI

– Merck Registry: cholesterol study

– Gusto V: acute MI

– Cohere: Coreg Heart Failure Registry

– Challenge: cholesterol study

– Paragon B: utilized lamifiban in patients that presented with
   USA/NQWMI

– OPUS: Utilized Orbofiban in patients with USA